Primary study · included by 1 review

Long-term survival outcomes of salvage [225Ac]Ac-PSMA-617 targeted alpha therapy in patients with PSMA-expressing end-stage metastatic castration-resistant prostate cancer: a real-world study.

Ballal 2023 · Ballal Sanjana, Yadav Madhav P, Satapathy Swayamjeet, et al. · European journal of nuclear medicine and molecular imaging · 2023

Included by

Beyond [177Lu]Lu-PSMA: a meta-analysis of safety and efficacy of emerging PSMA radioligand therapy agents.
Non-Cochrane · intervention · 2026 · cited as Ballal 2023 · Reference list refs 21-53; Table 2; Supplementary Table 5

The review does not say which of its outcomes this study informs.

1 including review in total.